Crinetics CMO Dana Pizzuti steps down; transitions to advisor roles with $577k severance

Crinetics Pharmaceuticals, Inc.

Dr. Dana Pizzuti steps down as CMO effective Dec 31, 2025; serves as Strategic Regulatory and Development Advisor through Mar 31, 2026.
Severance of $577,000 (12 months base salary) plus COBRA reimbursement and up to $15,000 in legal fees.
Advisor engagement from Apr 1, 2026 to Mar 30, 2028; $600/hour, up to 20 hours/month; equity continues to vest.
Transition duties include EU MAA approval for paltusotine (acromegaly), Brazil submission, and SKK Japanese application.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.